[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial. 

TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medicines, and the pancreatic cancer trial appears to have validated its therapeutic approach in a particularly difficult-to-treat cancer type.

Fundamentals

See More
  • Market Capitalization, $K 4,473,963
  • Shares Outstanding, K 144,648
  • Annual Sales, $ 62,380 K
  • Annual Income, $ -101,590 K
  • EBIT $ -111 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.19
  • Price/Sales 46.88
  • Price/Cash Flow N/A
  • Price/Book 7.45

Options Overview Details

View History
  • Implied Volatility 94.74% (-2.97%)
  • Historical Volatility 155.82%
  • IV Percentile 2%
  • IV Rank 12.26%
  • IV High 538.02% on 12/17/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 9) 3.61 (11.45%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 1,208
  • Volume Avg (30-Day) 360
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 8,497
  • Open Int (30-Day) 10,804
  • Expected Range 27.95 to 35.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.29
  • Low Estimate $-0.35
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.34 +63.17%
on 05/15/26
32.79 -3.75%
on 06/09/26
+8.54 (+37.10%)
since 05/08/26
3-Month
16.11 +95.90%
on 03/10/26
32.79 -3.75%
on 06/09/26
+15.11 (+91.85%)
since 03/09/26
52-Week
4.10 +669.76%
on 06/10/25
32.79 -3.75%
on 06/09/26
+27.40 (+658.65%)
since 06/09/25

Most Recent Stories

More News
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 28.07 (-10.83%)
JNJ : 237.00 (+2.08%)
INCY : 103.23 (+2.57%)
TNGX : 31.56 (+2.04%)
RHHBY : 50.2300 (-0.63%)
Tango Therapeutics Announces Proposed $500 Million Public Offering

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted...

TNGX : 31.56 (+2.04%)
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026...

TNGX : 31.56 (+2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 36.48
2nd Resistance Point 34.63
1st Resistance Point 33.10
Last Price 31.56
1st Support Level 29.72
2nd Support Level 27.87
3rd Support Level 26.34

See More

52-Week High 32.79
Last Price 31.56
Fibonacci 61.8% 21.83
Fibonacci 50% 18.44
Fibonacci 38.2% 15.06
52-Week Low 4.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.